<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04605666</url>
  </required_header>
  <id_info>
    <org_study_id>CAR-T-ALL-2020</org_study_id>
    <nct_id>NCT04605666</nct_id>
  </id_info>
  <brief_title>CD19-CAR-T2 Cells for CD19 Positive Acute Lymphoblastic Leukemia</brief_title>
  <official_title>CD19-Chimeric Antigen Receptor-T2 Cells for CD19 Positive Acute Lymphoblastic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanfang Hospital of Southern Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Relapsed and refractory B cell acute lymphoblastic leukemia (B-ALL) shows unfavorable&#xD;
      prognosis, especially for adult patients. Besides, minimal residual disease (MRD) positive at&#xD;
      transplant has been considered risk factor for relapse after transplantation. Worse yet,&#xD;
      there is no standard management for these patients. Chimeric antigen receptor T cells (CAR-T&#xD;
      cells) has been recognized a promising treatment option for treating B cell derived&#xD;
      malignancy. The purpose of this study is to evaluate the efficacy and safety of chimeric&#xD;
      antigen receptor 19 (CD19-CAR-T2 Cells) infusions in patients with CD19+ ALL.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ORR</measure>
    <time_frame>3 months</time_frame>
    <description>Overall Response Rate includes Complete Remission (CR) and Complete Remission with Incomplete Blood Count Recovery (CRi), as determined by assessments of peripheral blood, bone marrow, CNS symptoms, physical exam (PE) and CSF. The primary endpoint will be based on the IRC assessment. The local investigator's assessed results will be used for sensitivity analysis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>1 year</time_frame>
    <description>overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DFS</measure>
    <time_frame>1 year</time_frame>
    <description>disease-free survival</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Acute Lymphoblastic Leukemia, in Relapse</condition>
  <condition>Acute Lymphoblastic Leukemia Not Having Achieved Remission</condition>
  <condition>Acute Lymphoblastic Leukemia, Adult</condition>
  <arm_group>
    <arm_group_label>CAR-T group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CD19-CAR-T2 Cells</intervention_name>
    <description>CD19-CAR-T2 T cells will be infused over 10-15 minutes on Day 0.</description>
    <arm_group_label>CAR-T group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient with CD19 positive B-cell acute leukemia&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status &lt;2&#xD;
&#xD;
          -  ALT/ AST &lt;3 x normal&#xD;
&#xD;
          -  Bilirubin &lt; 2.0 mg/dl&#xD;
&#xD;
          -  Creatinine &lt; 2.5 mg/dl and less than 2.5x normal for age&#xD;
&#xD;
          -  LVEF&lt; 45%&#xD;
&#xD;
          -  Accept white blood cell collection&#xD;
&#xD;
          -  Provide informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous treatment with investigational gene or cell therapy medicine products&#xD;
&#xD;
          -  Active hepatitis B , hepatitis C or HIV infection&#xD;
&#xD;
          -  Uncontrolled active infection&#xD;
&#xD;
          -  Presence of grade 2-4 acute or extensive chronic GVHD&#xD;
&#xD;
          -  Active CNS involvement: epilepsy, paresis, aphasia, stroke, severe head trauma,&#xD;
&#xD;
          -  Dementia, Parkinson's disease, cerebellar disease, organic brain syndrome,&#xD;
             uncontrolled mental illness, etc.&#xD;
&#xD;
          -  Any uncontrolled active medical disorder that would preclude participation as&#xD;
             outlined.&#xD;
&#xD;
          -  Received non-diagnostic purposes major surgery within the past 4 weeks&#xD;
&#xD;
          -  Participated in any other clinical study within the past 4 weeks&#xD;
&#xD;
          -  Used murine biological products (except blinatumomab), unless it is proved no&#xD;
             anti-mouse antibodies exist.&#xD;
&#xD;
          -  Pregnancy or breast-feeding women&#xD;
&#xD;
          -  Use of prohibited drugs:&#xD;
&#xD;
          -  Steroids: Therapeutic doses of steroids must be stopped &gt; 72 hours prior to&#xD;
             CD19-CAR-T2 Cells infusion&#xD;
&#xD;
          -  Allogeneic cellular therapy: Any donor lymphocyte infusions (DLI) must be completed &gt;&#xD;
             4 weeks prior to CD19-CAR-T2 Cells infusion&#xD;
&#xD;
          -  GVHD therapies: Any drug used for GVHD must be stopped &gt; 4 weeks prior to CD19-CAR-T2&#xD;
             Cells infusion&#xD;
&#xD;
          -  Any situation that may increase the risk of the test or interfere with the test&#xD;
             results&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qi-fa Liu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nanfang Hospital of Southern Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ren Lin, MD</last_name>
    <phone>+86-020-62787883</phone>
    <email>lansinglinren@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nanfang Hospital, Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ren Lin, MD</last_name>
      <phone>+86-020-62787883</phone>
      <email>lansinglinren@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 25, 2020</study_first_submitted>
  <study_first_submitted_qc>October 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 28, 2020</study_first_posted>
  <last_update_submitted>October 25, 2020</last_update_submitted>
  <last_update_submitted_qc>October 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nanfang Hospital of Southern Medical University</investigator_affiliation>
    <investigator_full_name>Qifa Liu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>acute lymphoblastic leukemia</keyword>
  <keyword>minimal residual disease</keyword>
  <keyword>CAR-T</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

